Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR, TSX:TKM) is a leading RNA interference (RNAi) therapeutics company. With more than 14 years of industry experience, Tekmira is a global leader in the RNAi field. We are developing novel drugs in areas where there is a significant unmet medical need and commercial opportunity. We also license our leading lipid nanoparticle (LNP) delivery technology to partners around the world.
In light of Canada’s anti-spam legislation, which came into effect on July 1, 2014, we are required to obtain your express consent to send you commercial electronic messages. Please click on the following button to indicate consent. At any time, you can withdraw your consent at any time. To contact us, click here.